Letter from the Editor
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2012-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | https://www.tandfonline.com/doi/10.4161/hv.21698 |
| _version_ | 1797632965366251520 |
|---|---|
| author | Ronald Ellis Eva M. Riedmann |
| author_facet | Ronald Ellis Eva M. Riedmann |
| author_sort | Ronald Ellis |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:44:12Z |
| format | Article |
| id | doaj.art-01b88ab0ff9544a0bb4d953d1111d390 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:44:12Z |
| publishDate | 2012-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-01b88ab0ff9544a0bb4d953d1111d3902023-11-09T15:17:18ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2012-08-01881013101310.4161/hv.21698Letter from the EditorRonald Ellis0Eva M. Riedmann1Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, IsraelAcquisitions Editor; Landes Bioscience; Vienna, Austriahttps://www.tandfonline.com/doi/10.4161/hv.21698 |
| spellingShingle | Ronald Ellis Eva M. Riedmann Letter from the Editor Human Vaccines & Immunotherapeutics |
| title | Letter from the Editor |
| title_full | Letter from the Editor |
| title_fullStr | Letter from the Editor |
| title_full_unstemmed | Letter from the Editor |
| title_short | Letter from the Editor |
| title_sort | letter from the editor |
| url | https://www.tandfonline.com/doi/10.4161/hv.21698 |
| work_keys_str_mv | AT ronaldellis letterfromtheeditor AT evamriedmann letterfromtheeditor |